4-(2-fluoroethoxy)piperidine | 1220179-26-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(2-fluoroethoxy)piperidine
• CAS: 1220179-26-9
• 化学式: C₇H₁₄FNO
• 分子量: 147.193
• InChiKey: ZYWSJLKFJGIJGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二氯-5-(碘甲基)嘧啶 、 4-(2-fluoroethoxy)piperidine 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以30 mg的产率得到2,4-dichloro-5-((4-(2-fluoroethoxy)piperidin-1-yl)methyl)
  参考文献：
  名称：

  DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY

  摘要：

  The invention provides diazepino-thieno-quinoxaline compounds, pharmaceutical compositions, their use for inhibiting MK2, and their use in the treatment of a disease or condition, such as an inflammatory disorder.

  公开号：

  WO2024044731A1
• 作为产物：
  描述：

  tert-butyl 4-(2-fluoroethoxy)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 4-(2-fluoroethoxy)piperidine
  参考文献：
  名称：

  Synthesis and evaluation of an AZD2461 [18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant

  摘要：

  Poly(ADP-ribose)polymerase-1 inhibitor (PARPi) AZD2461 was designed to be a weak P-glycoprotein (P-gp) analogue of FDA approved olaparib. With this chemical property in mind, we utilized the AZD2461 ligand architecture to develop a CNS penetrant and PARP-1 selective imaging probe, in order to investigate PARP-1 mediated neuroinflammation and neurodegenerative diseases, such as Alzheimer's and Parkinson's. Our work led to the identification of several high-affinity PARPi, including AZD2461 congener 9e (PARP-1 IC50, = 3.9 +/- 1.2 nM), which was further evaluated as a potential F-18-PET brain imaging probe. However, despite the similar molecular scaffolds of 9e and AZD2461, our studies revealed non-appreciable brain-uptake of [F-18]9e in non-human primates, suggesting AZD2461 to be non-CNS penetrant.

  DOI：

  10.1016/j.bioorg.2018.10.015

文献信息

• DIHYDROPYRIDOPYRROLE DERIVATIVES AS TAU-PET-LIGANDS
  申请人：AC Immune S.A.

  公开号：EP3118202A1

  公开（公告）日：2017-01-18

  The present invention relates to novel compounds of formula (I) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other Tauopathies using Positron Emission Tomography (PET) Imaging. Formula (I):

  本发明涉及一种可以用于选择性Tau检测与Tau聚集物相关的疾病和异常，如阿尔茨海默病和其他Tau病理学，利用正电子发射断层扫描（PET）成像的新化合物的公式（I）。公式（I）：
• [EN] BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY<br/>[FR] COMPOSÉS BICYCLIQUES POUR DIAGNOSTIC ET TRAITEMENT
  申请人：AC IMMUNE SA

  公开号：WO2017153601A1

  公开（公告）日：2017-09-14

  The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A- synuciein, aSynuciein, A-syn, a-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

  本发明涉及可以用于诊断、监测疾病进展或监测药物活性的化合物(I)的公式，该化合物可用于与α-突触核蛋白（α-突触核蛋白，A-突触核蛋白，aSynuciein，A-syn，a-syn，aSyn）聚集相关的一组疾病和异常，包括但不限于Lewy小体和/或Lewy神经纤维，如帕金森病。这些化合物特别有助于确定对这种疾病的易感性，监测残留疾病，或预测患有这种疾病的患者对某种药物治疗的反应性。这些化合物还可用于治疗、缓解或预防与α-突触核蛋白聚集相关的疾病或异常。
• Discovery of 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c’]dipyridine ([18F]PI-2014) as PET tracer for the detection of pathological aggregated tau in Alzheimer’s disease and other tauopathies
  作者：Emanuele Gabellieri、Francesca Capotosti、Jerome Molette、Nampally Sreenivasachary、Andre Mueller、Mathias Berndt、Hanno Schieferstein、Tanja Juergens、Yvan Varisco、Felix Oden、Heribert Schmitt-Willich、David Hickman、Ludger Dinkelborg、Andrew Stephens、Andrea Pfeifer、Heiko Kroth

  DOI：10.1016/j.ejmech.2020.112615

  日期：2020.10

  The compound screening was initiated with a direct staining assay to identify compounds binding to Tau aggregates and not Abeta plaques using human brain sections derived from late stage Alzheimer's disease donors. The binding of Tau aggregate selective compounds was then quantitatively assessed with human brain derived paired helical filaments utilizing the label-free Back Scattering Interferometry assay. In vivo biodistribution experiments of selected fluorine-18 labeled compounds were performed in mice to assess brain uptake, brain washout, and defluorination. Compound 11 emerged as the most promising candidate, displaying high in vitro binding affinity and selectivity to neurofibrillary tangles. Fluorine-18 labeled compound 11 showed high brain uptake and rapid washout from the mouse brain with no observed bone uptake. Furthermore, compound 11 was able to detect Tau aggregates in tauopathy brain sections from corticobasal degeneration, progressive supranuclear palsy, and Pick's disease donors. Thus, 2-(4-(2-fluoroethoxy)piperidin-1-yl)-9-methyl-9H-pyrrolo[2,3-b:4,5-c']dipyridine (PI-2014, compound 11) was selected for characterization in a first-in-human study. (C) 2020 Elsevier Masson SAS. All rights reserved.
• BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY
  申请人：AC Immune SA

  公开号：EP3426653B1

  公开（公告）日：2021-12-15
• [EN] NOVEL IMAGING COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS D'IMAGERIE
  申请人：AC IMMUNE SA

  公开号：WO2017009454A1

  公开（公告）日：2017-01-19

  The present invention relates to novel compounds that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.